2'-O-butyladenosine | 116525-69-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-O-butyladenosine
• 英文别名: (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-butoxy-2-(hydroxymethyl)oxolan-3-ol
• CAS: 116525-69-0
• 化学式: C₁₄H₂₁N₅O₄
• 分子量: 323.352
• InChiKey: AWOAENKSQYFOLM-IDTAVKCVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2'-O-butyladenosine 在 吡啶 、 三甲基氯硅烷 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 Diisopropyl-phosphoramidous acid (2R,3R,4R,5R)-5-(6-benzoylamino-purin-9-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-butoxy-tetrahydro-furan-3-yl ester 2-cyano-ethyl ester
  参考文献：
  名称：

  Investigations on the influence of 2′-O-alkyl modifications on the base pairing properties of oligonucleotides

  摘要：

  DOI：

  10.1016/s0031-6865(97)00041-1
• 作为产物：
  描述：

  1-碘丁烷 、 腺苷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以48%的产率得到2'-O-butyladenosine
  参考文献：
  名称：

  Investigations on the influence of 2′-O-alkyl modifications on the base pairing properties of oligonucleotides

  摘要：

  DOI：

  10.1016/s0031-6865(97)00041-1

文献信息

• Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0269574A2

  公开（公告）日：1988-06-01

  The present invention relates to novel adenosine derivatives having the formula (I): wherein each of R₁, R₂ and R₃, which may be the same or different, is hydrogen or a lower alkyl group; X is hydrogen, a lower alkyl group, an amino group or halogen; and Y is hydrogen or a lower alkyl group; and pharmaceutically acceptable salt thereof. These compounds are useful as antihypertensive agents, for example, for the treatments of hypertension and various diseases caused by hypertension, such as cerebrovascular diseases, cardiopathy or renal insufficiency.

  本发明涉及具有式(I)的新型腺苷衍生物：其中，R₁、R₂和R₃可以相同或不同，各自为氢或低级烷基；X为氢、低级烷基、氨基或卤素；Y为氢或低级烷基；及其药学上可接受的盐。 这些化合物可用作降压药，例如，用于治疗高血压和高血压引起的各种疾病，如脑血管疾病、心脏病或肾功能不全。
• Adenosindeaminase inhibitor
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0601322A2

  公开（公告）日：1994-06-15

  The use of a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof wherein each of R₁, R₂ and R₃ which may be same or different is hydrogen or alkyl; and R and X have the meanings given in the specification, for the preparation of a medicament which is an adenosinedeaminase inhibitor is disclosed. Some of the compounds of formula (I) are novel compounds. They may be used for the making of a medicament which is for the prevention or therapy of ischemic heart diseases, diseases caused by cerebrovascular disorders, renal diseases and allergic diseases and of post-operative complicated diseases involved with activated oxygen which is generated in ischemic areas during the recirculation of blood after operations.

  使用以下通式（I）代表的化合物或其药学上可接受的盐 其中R₁、R₂和R₃可以相同或不同，各自为氢或烷基；R和X具有说明书中给出的含义。一些式（I）化合物是新型化合物。它们可用于制备预防或治疗缺血性心脏病、脑血管疾病、肾脏疾病和过敏性疾病以及术后复杂疾病的药物，这些疾病与术后血液再循环过程中在缺血区域产生的活性氧有关。
• Compositions and methods for detecting and modulating rna activity and gene expression
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1418179A2

  公开（公告）日：2004-05-12

  Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferably accomplished. Therapeutics, diagnostics and research methods are also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.

  本文公开了调节 RNA 和 DNA 活性的组合物和方法。根据优选的实施方案，反义组合物由靶向部分和反应部分组成。反应部分最好通过磷酸二酯键裂解、骨架糖键裂解或碱基修饰起作用。根据本发明的某些实施方案，改善寡核苷酸药效学和药代动力学特性的基团也是有用的。最好还能将反应性或非反应性官能团输送到组合物与目标 RNA 杂交形成的次凹槽中。本发明还公开了治疗、诊断和研究方法。本发明还提供了合成核苷和核苷片段，可用于制备用于上述目的的寡核苷酸和寡核苷酸类似物。
• ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3998108A1

  公开（公告）日：2022-05-18

  The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5' and/or 3' end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).

  本发明的目的是建立一种治疗面肱骨肌营养不良症的新型疗法。 一种寡核苷酸或其药学上可接受的盐，其中寡核苷酸包括由与 DUX4-fl mRNA 的核苷酸 Nos.寡核苷酸的 5'端和/或 3'端可进行化学修饰；并且寡核苷酸能够将 DUX4 基因的剪接形式从 DUX4-fl 转换为 DUX4-s。一种包含上述寡核苷酸或其药学上可接受的盐的药物（如治疗面肱骨肌营养不良症）。
• GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP4029520A1

  公开（公告）日：2022-07-20

  The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.

  本发明提供了一种寡核苷酸的共轭物，该寡核苷酸具有可望在肝实质细胞中产生药理作用的核酸序列，带有一个双年基 GalNAc 单元，或其药学上可接受的盐，以及一种含有相同的寡核苷酸作为活性成分的药物或类似物。